Evaluate the safety and effectiveness of adult autologous bone marrow mononuclear and mesenchymal stem cells in patients with chronic heart failure.
Introduction
Cardiovascular disease is the leading cause of death in the world [1, 2] . It represents a continuum of disease entities whose medical treatments differ [3] . Chronic heart failure affects up to 30 million people worldwide and highlights the growing burden of degenerative diseases at a global scale [4] . About 1-2% of adults in developed countries suffer from heart failure, with prevalence rising to 10% in persons 70 years of age or older. Liable for 42 million yearly hospitalizations in the United States and Europe, heart failure is a primary indication for repeated in hospital care across geographies [5] .
The therapeutic options for patients who develop advanced Heart Failure (HF) are limited to heart transplantation or the use of ventricular assist devices [5] . This results in a large HF patient population with progressive symptoms and limited treatment options [6] . Biologically based cell and gene therapies for advanced HF have shown promise [7] [8] [9] [10] . Cell therapy is a 21 st century approach to treat cardiovascular disease and is being applied worldwide. HF therapy entails syndrome relief, prevention of hospital admission and mortality reduction [8] .
Percutaneous Retrograde Coronary Sinus Perfusion (PRCSP) is a well-established technique for delivery of cardioplegia solution in cardiovascular surgery and for protection against myocardial ischemia, heart failure in patients undergoing high risk Percutaneous Coronary Intervention (PCI) [10, 11] .
The technique has the potential advantages of safety delivering a larger number of cells with more homogeneous delivery across the myocardium in patients with heart failure, AMI, refractory angina despite the presence of severe underlying coronary artery disease, valvular disease or previous myocardial infarction which may complicate delivery by either intracoronary or intramyocardial approach [11, 12] .
In 2002, the publications of Dr. Bodo Strauerr in Germany inspired our group to begin the investigation about the feasibility of practicing autologous stem cells implants by intra arterial coronary injection with the objective of producing angiogenesis and myogenesis according to the pathology to be treated.
In this study, we describe a report of 2 cases with chronic heart failure functional class IV, those were implanted with Bone Marrow Total Nucleated Stem Cells (BM-TNCs) by the retrograde technique.
Implantation of adult bone marrow stem cells is one of the options for treatment for congestive heart failure patients. The main goal is to evaluate the safety and effectiveness of adult autologous bone marrow mononuclear and mesenchymal stem cells in patients with chronic heart failure. A descriptive study with two patients, one with 71 and other with 88 years old has a history of acute revascularized myocardial infarction, heart failure functional class IV, severe dilated cardiomyopathy, severe impairment of the left ventricular fraction ejection and biventricular dysfunction. Both patients underwent implantation and infusion of adult and autologous adult bone marrow stem cells through the retrograde venous technique, by femoral venous catheterization. To obtain pre/post implantation results doppler echocardiograms and an exercise ergometry tests were conducted (com pared at 7 th and 12 th months). Holter ECG also evaluated at 6 th and 12 th months for each patient. The results shows a significant improvement in FEVI with approximately 12% and 17% with respect to baseline (P 0.05) and a decrease in heart mass from 411 to 334g and from 302 to 198g of each patient in a period of 365 days. After the implantation, there was a remarkable improvement in the quality of life of patients. With these two cases, it has been concluded that autologous adult bone marrow stem cells implantation is one of the safest and promising therapeutic options to treat congestive heart failure functional class IV without modifications in pharmacological medication.
IV, severe dilated cardiomyopathy, with severe impairment of the left ventricular fraction ejection (FEY-FEVI) (<30%) who suffered hospitalizations every 15 days, due to biventricular dysfunction.
The bone marrow harvesting cell preparation
Cells were extracted from the patient's own bone marrow. The left iliac crest puncture was performed under local anesthesia with lidocaine 1% with no epinephrine. A total up to 150ml of bone marrow was aspirated into 0.1ml heparin and 1ml citrated sodium 20ml syringes containing. The bone marrow aspirate was shipped at room temperature to the central cell-processing laboratory and 120ml was diluted with sterile 0.9% NaCl (1:1), filtrated through 70mm cell strainer and bone marrow total nucleated cells were isolated and enriched by density gradient with the use of Ficoll-Paque Premium (GE Healthcare Ltd.) according to the manufacturer's instruction. The BM-TNCs were washed 2 times with 45ml sterile DPBS (Hanks Sal Solution). During density gradient centrifugation, plasma factors, red blood cells and platelets were removed. Dose of 550.000.000 (Citometry: CD34+ CD38-: 22.000.000) (P.71 year old) and 770.000.000 (Citometry: CD34+ CD38: 17.000.000) (P.88 year old) of BM-TNCs were obtained (Figures 1 & 2) . BM-TNCs were diluted in a volume of 50ml with saline solution and were reinjected in each patient. Both patients underwent implantation and infusion of autologous adult bone marrow stem cells through the retrograde venous technique in the coronary sinus with occlusion of the same with a balloon, by femoral venous catheterization (Figures 3 & 4) . Doppler echocardiograms were obtained pre/post implantation for comparisons (7 and 12 months), an exercise ergometry test (Naughton Test) post implant (6 months) and evaluation of Holter ECG at 6 and 12 months for each patient. Figure 5 and table 1 shows that after a 365 days period, there was a significant improvement in the FEVI of approximately 12% and 17% with respect to baseline (P = 0.05) and a decrease in heart mass from 411 to 334g from 302 to 198g of each patient.
Results
In addition, it was observed that there was no recurrence in hospital readmissions every 15 days, due to HF, and that there was a marked improvement in the quality of life quickly after implantation of stem cells due to dyspnea modification Functional Class (FC) IV to III-II (NYH Classification) staying for at least one year. The post-implant ergometry test, at 180 days, proved to be encouraging, since both patients tolerated the stress test greater than 6 minutes. No arrhythmias were observed in the Holter ECG of each patient at 6 and 12 months.
There was no modification of the pharmacological medication during the follow-up of this descriptive and observational study. in the number of hospital re-admissions of the patients and demonstrated an improvement in the quality of life after modification of the FC of dyspnea from IV to III/II, staying for at least one year. It was corroborated that there is a significant increase of the FEVI from 12% to 17%, concomitantly with a decrease in heart mass. There were no presences of arrhythmias. It could be affirmed after a follow-up of 365 days of each patient.
The implant of autologous adult Bone Marrow Mononuclear and Mesenchymal Stem Cells (BM-TNCs) generated a favorable decrease

Discussion
This is an observational, descriptive, controlled and not blinded trial, where 2 patients received intra arterial infusion of BM-TNCs by retrogragrade venous technique.
Preclinical studies have demonstrated that total occlusion of the coronary sinus for up to 60 minutes is safe owing to the presence of the Thebesian veins, which also drain cardiac venous blood. Zakharova et al., also recently demonstrated the preclinical feasibility of retrograde cell delivery with distribution throughout the left ventricle [13] .
Retrograde coronary vein way to injection seems to be an excellent method of implanting stem cells in order to carry these cells to improper areas, badly perfunded by coronary arterial system, since this system is, because of its inadequacy, unable to irrigate certain areas where it is necessary to implant cells.
This group of patients of the study with refractory cardiac failure, in spite of having in most cases secondary scars to chronic myocardial infarction, had viable areas that could not be revascularized. The cellular implantation had demonstrated true improvement of the perfusion, surely through angiogenesis, which was without any doubt responsible for the improvement of contractility of viable sectors.
However there is a difficulty to show an evidence of existing new angiogenesis to corroborate our hypothesis.
Human bone marrow is composed of cells and an extracellular matrix that contains cytokines and growth factors. The cellular component of bone marrow is composed of differentiated cells, such as monocytes, lymphocytes, fibroblasts, adipocytes, chondroblasts, osteoblasts, and osteoclasts, as well as a fractionally small but very diverse group of undifferentiated cells. The undifferentiated stem cell population is composed of hematopoietic stem Cells (hsC), which include hemangioblasts and endothelial Progenitor Cells (ePC), and nonhematopoietic Mesenchymal Precursor Cells (MPCs) that give rise to stromal cells referred to as Mesenchymal Stem Cells (MSCs). The undifferentiated stem cell population can be isolated from differentiated cells by density gradient centrifugation. The end product of this centrifugation process is referred to as bone marrow total nucleated cells and contains the undifferentiated hsC and MSC as well as a few committed cells in various stages of maturation. The overall structure of BM-TNCs is primarily that of early committed cells, with only 2% to 4% comprised of hsC/ePC and approximately 0.01% of MSC [13] .
Cells-based therapies have been considered overall safe procedures. A recent systematic review of 36 prospective clinical trials for several clinical conditions, including myocardial infarction and chronic cardiomyopathy, did not detect an association between intravascular infusions of mesenechymals or total nucleated cells and the risk of acute infusion toxicity, organ system complications, infection, death, or malignancy in treated patients. Systematic reviews in heart failure population actually describe an association between stem cell therapy and a reduction of mortality and major cardiovascular events albeit most of the analyzed studies used intramyocardial injection or percutaneous intracoronary infusion of bone marrow mononuclear cells [14] . In this investigation, there were no side effects during and after the stem cell implantation procedures for at least 365 days.
Garzon FB et al., published that left ventricular function shows favorable changes after regenerative treatment of infarction and dilated cardiomiopathy. However, no correlation was found between changes in micro vascular and myocardial function after regenerative therapy [15] .
Strauer BE, et al., confirmed that the use of unselected BM-derived Mononuclear Cells (BMCs) is clearly the most examined cardiac cell-based therapy in clinical studies with a clinical follow-up experience up to 5 years [16, 17] . In 2005, our group of investigators from San Nicolas City, Argentina, showed safety and feasibility of mononuclear stem cells-based therapy in cardiac diseases [17] .
Conclusion
The implantation of autologous adult bone marrow stem cells is a safe and a promising therapeutic option for the treatment of congestive heart failure functional class IV, refractory to pharmacological treatment, although more clinical studies are necessary to confirm the findings. 
